Crescent Biopharma CBIO
NASDAQ CBIO
$13.17 +0.10 (+0.77%)
At close: Oct 21, 2026 · 4:00 PM EDT

Crescent Biopharma (CBIO) Current Deferred Revenue (2025 - 2026)

Updated

Crescent Biopharma's Current Deferred Revenue came in at $3.12 million for Q2 2026, unchanged from the prior quarter.

Analysis

Crescent Biopharma (CBIO) Current Deferred Revenue (2025 - 2026) Analysis & Trends

At the end of FY2025, Crescent Biopharma's Current Deferred Revenue was $4.16 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Crescent Biopharma 401.19 Mn -306.10 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 3.12 Mn
Mar 31, 2026 3.12 Mn
Dec 31, 2025 4.16 Mn
API Access

Crescent Biopharma Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=CBIO&period=max&api_key=YOUR_API_KEY